Koers Mateon Therapeutics, Inc. Other OTC
Aandelen
MATN
US57667K1097
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | 0,07 0,06 | Marktkapitalisatie | 15,27 mln. 14,01 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 5 mln. 4,59 mln. | Nettowinst (verlies) 2023 | -7 mln. -6,42 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 11,02 mln. 10,11 mln. | Nettoschuld 2023 | 12,4 mln. 11,38 mln. | EV/omzet 2023 | 395.316.686 x |
K/w-verhouding 2022 |
4,5
x | K/w-verhouding 2023 |
-1,91
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 45,17% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Director of Finance/CFO | 57 | 01-07-19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06-01-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 11-05-20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-05-20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |